Lifeboat Foundation

My idea is that all the waste from human waste has vital things in it we could even someday have everything recycled back into its original form like if waste medicines or other nutrients could be extracted we could essentially recycle human waste having a near unlimited supply of chemicals which would be great for space traveling where nothing is wasted.

Poop’s got an image problem

And there’s also the issue of acceptance. Research suggests there are both cultural and psychological barriers standing in the way of wider bodily waste recycling.

Continue reading “Recycling our poop to grow food more sustainably” »

Dr. Fasiha Kanwal discusses what you need to know about liver cancer detection and screening.

A study from Ann & Robert H. Lurie Children’s Hospital of Chicago demonstrated that Botulinum toxin (Botox) injected in the pylorus during endoscopy improves chronic nausea and vomiting in children who have a disorder of gut-brain interaction (DGBI). These debilitating symptoms not attributed to a defined illness have previously been called functional gastrointestinal disorders before the newer DGBI classification. The study’s findings point to a novel understanding of the condition’s pathology – pylorus that is failing to relax and allow food to effectively pass into the small intestine resulting in symptoms of nausea, vomiting, early satiety and bloating.

Results were published in the Journal of Pediatric Gastroenterology and Nutrition.

“Our results suggest that chronic nausea and vomiting might be caused by pyloric dysfunction, rather than abnormal peristalsis, which is the rhythmic contraction and relaxation of digestive tract muscles needed to move foods and liquids through the gastrointestinal system,” said lead author Peter Osgood, MD, gastroenterologist at Lurie Children’s and Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine. “This is a paradigm shift in our understanding of mechanistic pathology. Importantly, it opens the door to a more targeted use of Botox specifically in children who are found to have pyloric dysfunction during endoscopy, and for whom the current medications are not effective.”

The dean of Stanford University’s medical school thinks artificial intelligence will transform the medicines you take, the care you get, and the training of doctors.

A team of New York University computer scientists has created a neural network that can explain how it reaches its predictions. The work reveals what accounts for the functionality of neural networks—the engines that drive artificial intelligence and machine learning—thereby illuminating a process that has largely been concealed from users.

The breakthrough centers on a specific usage of neural networks that has become popular in recent years—tackling challenging biological questions. Among these are examinations of the intricacies of RNA splicing—the focal point of the study—which plays a role in transferring information from DNA to functional RNA and protein products.

“Many neural networks are black boxes —these algorithms cannot explain how they work, raising concerns about their trustworthiness and stifling progress into understanding the underlying biological processes of genome encoding,” says Oded Regev, a computer science professor at NYU’s Courant Institute of Mathematical Sciences and the senior author of the paper, which was published in the Proceedings of the National Academy of Sciences.

Remote control of chemical reactions in biological environments could enable a diverse range of medical applications. The ability to release chemotherapy drugs on target in the body, for example, could help bypass the damaging side effects associated with these toxic compounds. With this aim, researchers at California Institute of Technology (Caltech) have created an entirely new drug-delivery system that uses ultrasound to release diagnostic or therapeutic compounds precisely when and where they are needed.

The platform, developed in the labs of Maxwell Robb and Mikhail Shapiro, is based around force-sensitive molecules known as mechanophores that undergo chemical changes when subjected to physical force and release smaller cargo molecules. The mechanical stimulus can be provided via focused ultrasound (FUS), which penetrates deep into biological tissues and can be applied with submillimetre precision. Earlier studies on this method, however, required high acoustic intensities that cause heating and could damage nearby tissue.

To enable the use of lower – and safer – ultrasound intensities, the researchers turned to gas vesicles (GVs), air-filled protein nanostructures that can be used as ultrasound contrast agents. They hypothesized that the GVs could function as acousto-mechanical transducers to focus the ultrasound energy: when exposed to FUS, the GVs undergo cavitation with the resulting energy activating the mechanophore.

Amid the ongoing SAG strike, Tom Hanks has issued a warning about an AI version of him being used in a dental ad without his consent.

Tap through to read how, for almost 30 years, a world-leading gait analysis laboratory at The Royal Children’s Hospital, Melbourne has helped children with cerebral palsy receive life-changing treatments → unimelb.me/45ez4RT

For almost 30 years, a world-leading gait analysis laboratory at The Royal Children’s Hospital in Melbourne has helped children with cerebral palsy receive life-changing treatments.

When Professor Kerr Graham arrived in Australia to introduce gait analysis technology to help manage children with cerebral palsy, some medical professionals were sceptical. An accomplished orthopaedic surgeon who had trained in Ireland, London and Toronto, Professor Graham had witnessed firsthand the dramatic potential of gait analysis to improve the lives of children with cerebral palsy.

Continue reading “Helping children with cerebral palsy put their best foot forward” »

All medical breakthroughs have to start somewhere, and Intellia Therapeutics is ready to show the world the first-in-human gene editing data that could be the start of a | Interim results are in for Intellia and partner Regeneron’s in vivo CRISPR/Cas9 genome editing candidate, NTLA-2001, in patients with transthyretin (ATTR) amyloidosis: and the numbers look good. This is the first time gene editing has been proven to work in humans, which “opens up a whole new area of therapies for patients that wasn’t there.”